Douglas G. Watson

This profile gathers the share dealings of Douglas G. Watson across 8 companies, led by Biomimetic Therapeutics, Inc., Dendreon Corp and Orasure Technologies Inc. In total, 129 filings cover trades dated from 15 March 2006 to 13 November 2016.

The open-market side counts 11 purchases for €138k alongside 18 sales for €4.0M. The net balance comes to €3.9M on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 27 share grants and 66 option exercises.

In size, the median ticket on the buying side is €5,137.

The latest filing, published on 16 November 2016, reports a transaction in Orasure Technologies Inc. The last purchase on record was published on 4 June 2012, which is 5,254 days ago. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.